TX-MARY-KAY
20.6.2024 18:04:28 CEST | Business Wire | Press release
Mary Kay Inc., a global leader in skin care innovation, recently revealed the results of two breakthrough research studies: first, an antioxidant treatment that can diminish the visible effects of pollution and aging on human skin; and second, a focus on the applications of computational tools to accurately predict the safety and potential reactions of human skin to various cosmetic ingredients. These findings were shared by Mary Kay scientists at the 2024 Society of Investigative Dermatology (SID) meeting in Dallas, Texas. The company was a silver-level sponsor of the event.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240620935246/en/
Mary Kay Inc. recently revealed the results of two breakthrough research studies at the 2024 Society of Investigative Dermatology. (Photo: Mary Kay Inc.)
“Mary Kay scientists are at the forefront of skin care research, and we’re pleased to share our latest findings with the broader scientific community,” said Dr. Lucy Gildea, Chief Innovation Officer, Product & Science at Mary Kay. The ongoing partnership with the Society of Investigative Dermatology underscores Mary Kay’s dedication to advancing skincare science. By maintaining collaborative efforts, the company remains steadfast in its commitment to making significant breakthroughs in the field of dermatology, ultimately providing consumers with safer and more effective skincare solutions.
“Mary Kay's enduring commitment to research and development aligns perfectly with our goals at the Society for Investigative Dermatology," said Dr. Rebecca Minnillo, Chief Program, Communications and Development Officer at SID. "Our sustained partnership enables us to explore new frontiers in dermatological science, bringing us closer to breakthroughs that can transform skin care and treatment options.”
Mary Kay's research into the effects of air pollution on skin, conducted through multiple academic collaborations since 2016, revealed that an antioxidant blend of resveratrol, niacinamide, and oligopeptide-1 protects natural skin surface lipids from oxidative damage caused by particulate matter (PM) and UV radiation, both alone and combined. Additionally, this blend has been found to prevent free radical formation induced by blue light, demonstrating its potential in mitigating the detrimental effects of multiple environmental stressors on the skin.
Furthermore, Mary Kay is leveraging computational toxicology tools to enhance ingredient safety assessment of cosmetic and personal care ingredients. This innovative approach involves the use of advanced computational methods to predict the safety and potential toxicity of ingredients at an early stage, significantly reducing the need for extensive laboratory testing. Virtual screening allows for the early screening of compounds, ensuring only safe ingredients proceed in the development process. This method not only saves time and resources but also aligns with ethical and regulatory standards. By integrating these advanced tools, Mary Kay underscores its commitment to leveraging cutting-edge technology for product development, ensuring the highest standards of safety and efficacy for its consumers.
Mary Kay’s Dr. Gildea also hosted a compelling panel at SID, titled "Insights into the Effects of Pollution on Skin Health: Recent Discoveries & Emerging Perspectives,” comprising experts from varied fields of dermatology and molecular biology. Panelists included Dr. Thomas Haarmann-Stemmann, Group Leader at the Leibniz Research Institute for Environmental Medicine, who discussed the link between increased ambient temperature and skin aging. Dr. Elma Baron, Associate Professor of Dermatology at Case Western Reserve University, emphasized the significance of topical antioxidants in mitigating oxidative stress and improving skin health. Dr. Hong Sun, Assistant Professor at NYU Grossman School of Medicine, delved into molecular changes in skin cells exposed to environmental stressors, demonstrating the efficacy of antioxidant treatments in reversing gene expression changes associated with skin damage induced by UV and pollution exposure.
The sponsorship and findings presented at the 2024 SID meeting represent the latest efforts by Mary Kay to reinforce the brand’s long-standing commitment to advancing research and development in skin health and beauty. With over 1,600 patents for products, technologies, and packaging designs in its global portfolio, Mary Kay continues to lead the way in skincare innovation.
About Mary Kay
Then. Now. Always. One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty brand in Texas in 1963 with one goal: to enrich women’s lives. That dream has blossomed into a global company with millions of independent sales force members in more than 35 countries. For 60 years, the Mary Kay opportunity has empowered women to define their own futures through education, mentorship, advocacy, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in preserving our planet for future generations, protecting women impacted by cancer and domestic abuse, and encouraging youth to follow their dreams. Learn more at marykayglobal.com, find us on Facebook, Instagram, and LinkedIn, or follow us on Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240620935246/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mobix Labs Signs Definitive Agreement to Acquire Vision Aerial, Accelerating Global Drone Platform for National Security and Aerial Intelligence24.7.2026 13:00:00 CEST | Press release
Transaction accelerates Mobix Labs’ global aerial intelligence strategy and National Security Matters Initiative Mobix Labs, Inc. (Nasdaq: MOBX) today announced that it has signed a definitive agreement to acquire Vision Aerial, Inc., a U.S.-based designer and manufacturer of American-built, National Defense Authorization Act (NDAA)-compliant unmanned aerial systems. The definitive agreement moves the transaction beyond the previously announced letter of intent and represents a major step toward closing an acquisition that would expand Mobix Labs into one of the world’s most important technology growth markets: secure drones, autonomous aerial systems and aerial intelligence for national security, critical infrastructure, energy, public safety, industrial inspection and government operations. Vision Aerial’s customers and end-users include the U.S. Air Force, U.S. Navy, government agencies, energy and utility operators, research institutions and other organizations requiring performanc
Enhertu® Plus Pertuzumab Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with HER2 Positive Metastatic Breast Cancer24.7.2026 13:00:00 CEST | Press release
Recommendation based on DESTINY-Breast09 phase 3 trial results that showed Enhertu plus pertuzumab reduced the risk of disease progression or death by 44% versus THP with a median progression-free survival exceeding three years If approved, Daiichi Sankyo and AstraZeneca’s Enhertu plus pertuzumab would become first new treatment in the EU in more than a decade for first-line HER2 positive metastatic breast cancer Enhertu® (trastuzumab deruxtecan) in combination with pertuzumab has been recommended for approval in the European Union (EU) for the first-line treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP)
SLB Announces Second-Quarter 2026 Results24.7.2026 12:50:00 CEST | Press release
Revenue of $8.97 billion increased 3% sequentially and 5% year on year GAAP EPS of $0.52 increased 4% sequentially and decreased 30% year on year EPS, excluding charges and credits, of $0.55 increased 6% sequentially and decreased 26% year on year Net income attributable to SLB of $786 million increased 5% sequentially and decreased 22% year on year Adjusted EBITDA of $1.90 billion increased 7% sequentially and decreased 7% year on year Cash flow from operations was $1.36 billion and free cash flow was $716 million Board approved quarterly cash dividend of $0.295 per share SLB (NYSE: SLB) today announced results for the second-quarter 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722694386/en/ The exterior of the SLB headquarters in Houston, Texas.Second-Quarter Results(Stated in millions, except per share amounts)Three Months EndedChangeJun. 30, 2026Mar. 31, 2026Jun. 30, 2025SequentialYear-on-yearRevenue $8,972 $8
NIQ Expands GenAI Capabilities Across gfknewron, Turning Trusted Intelligence into Decisions Faster24.7.2026 12:30:00 CEST | Press release
New capabilities help businesses uncover trends faster, simplify complex analysis, and accelerate confident decision-making NIQ (NYSE: NIQ), a leader in consumer intelligence, today announced the expansion of AI-powered Smart Insights across its gfknewron® platform. By bringing together markets and categories into a single view, gfknewron enables businesses to transform complex market, consumer and supply chain data into clear, actionable intelligence quickly. The latest enhancements help users identify trends, opportunities and performance drivers more quickly, reducing the time required to analyze large datasets and accelerating confident decision-making across teams. As brands and retailers face growing pressure to respond quickly to changing consumer behavior and market dynamics, the ability to unlock meaningful insights from increasingly rich datasets has become a significant competitive advantage. As AI is only as effective as the intelligence behind it, Smart Insights helps busi
Thales to Strengthen Romania’s Airspace Protection With Twelve Ground Master 200 MM/A Radars24.7.2026 10:05:00 CEST | Press release
The Romanian General Directorate for Armaments and the French Direction Générale de l’Armement (DGA – the French defence procurement agency) have signed an agreement to supply twelve Thales GM200 Multi-Mission All-in-one (GM200 MM/A) radars to protect the Romanian airspace. This government-to-government agreement underlines the high level of partnership between France and Romania, within the framework of the European Union’s SAFE funding programme, in order to bolster Europe’s defence capabilities. The GM200 MM/A is part of Thales’ proven Ground Master radar family, which has already been deployed in over 40 countries, including now in Romania. In a context of growing collaboration between European nations to bolster collective security, the Romanian General Directorate for Armaments has just signed a landmark agreement with France’s Direction Générale de l’Armement (DGA) to acquire twelve Thales Ground Master 200 Multi-Mission All-in-one (GM200 MM/A) radars. This government-to-governm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom